Stemchymal
Phase 2Biologic
Stemchymal is one of 6 biologic programs targeting Cerebellar Ataxia. It is currently in Phase 2.
1
Indications
3
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
5 competitors in Cerebellar Ataxia
#DrugCompanyPhaseTrials
1Rilutek
AAzurity Pharmaceuticals
Phase 3
Fampridine
BiogenPhase 3
Stemchymal
SSteminent Biotherapeutics Inc.
Phase 2
Ampyra
MMerz North America, Inc.
Preclinical
Conventional Medicine
JJaseng Medical Foundation
Preclinical
BHV-4157
BBiohaven Therapeutics Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Stemchymal. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- SSteminent Biotherapeutics Inc.